The biopharma sector is facing a significant wave of layoffs in 2024, affecting thousands of employees across various companies. This trend is shaped by numerous internal and external factors, including corporate restructuring, market adaptations, strategic divestments, and cost-saving measures.
The biopharmaceutical manufacturing sector stands at the brink of a revolution, driven by the relentless pursuit of speed, safety, and scalability. The emergence of new therapeutic modalities, coupled with the increasing demand for rapid and cost-effective production solutions, has necessitated a
Catalent, a prominent contract development and manufacturing organization (CDMO), has announced the divestment of its Somerset, New Jersey, oral solids development and small-scale manufacturing facility to Ardena, a Belgian CDMO. This transaction marks Ardena's entry into the U.S. market and
The pharmaceutical packaging industry stands at the precipice of a significant transformation. With an anticipated growth from $110.55 billion in 2024 to $176.94 billion by 2032, driven by the increasing prevalence of biologics, stringent regulations, and the menace of drug counterfeiting, it is
The biopharmaceutical industry is undergoing a significant transformation as it seeks to develop affordable treatments for unmet medical needs. Amidst this change, manufacturers are being pushed to cut costs and implement sustainable practices. Tosoh Bioscience stands out as a leader in sustainable
The landscape of respiratory syncytial virus (RSV) vaccination has seen significant developments with GSK's Arexvy vaccine leading the charge. Dive deep into the three-year efficacy data released by GSK, and understand what it means for the future of RSV vaccination, market dynamics, and public
